<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00988559</url>
  </required_header>
  <id_info>
    <org_study_id>J0866</org_study_id>
    <secondary_id>P50CA098252</secondary_id>
    <secondary_id>1R21CA128232</secondary_id>
    <secondary_id>NA_00020850</secondary_id>
    <nct_id>NCT00988559</nct_id>
  </id_info>
  <brief_title>Therapeutic Vaccination for Patients With HPV16+ Cervical Intraepithelial Neoplasia (CIN2/3)</brief_title>
  <official_title>A Pilot Study of pnGVL4a-CRT/E7 (Detox) for the Treatment of Patients With HPV16+ Cervical Intraepithelial Neoplasia 2/3 (CIN2/3)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institutes of Health (NIH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will test the efficacy and safety of different routes of administration of a DNA
      vaccine in patients with HPV16+ CIN2/3. Subjects will be enrolled in one of six treatment
      groups. Subjects enrolled in the first two groups will receive vaccination intradermally with
      a needle-free delivery device. Subjects enrolled in groups 3 and 4 will receive vaccination
      intramuscularly. Subjects enrolled in groups 5 and 6 will receive vaccine intralesionally.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Primary Objectives

        -  To evaluate the feasibility and toxicity of vaccination in women with CIN2/3 caused by
           HPV16

        -  To evaluate the effect of vaccination on histology

        -  To compare immunogenicity of three different routes of administration: intradermal (ID),
           intramuscular (IM), intralesional (IL).

      Secondary Objectives:

        -  To evaluate changes in HPV viral load

        -  To evaluate the cellular immune response to vaccination

        -  To evaluate the humoral immune response to vaccination

        -  To evaluate local tissue immune response

        -  To correlate measures of immune response with clinical response

        -  To correlate measures of immune response with those observed in the preclinical model
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2009</start_date>
  <completion_date type="Actual">July 2016</completion_date>
  <primary_completion_date type="Actual">July 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Related Serious Adverse Events</measure>
    <time_frame>9 months</time_frame>
    <description>Presence of intervention-related serious adverse events as defined by CTCAE</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Absence of CIN2/3 Lesion by Week 15</measure>
    <time_frame>15 weeks</time_frame>
    <description>Number of participants with no CIN2/3 lesion at the week 15 visit</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">132</enrollment>
  <condition>HPV16 Positive</condition>
  <condition>Cervical Intraepithelial Neoplasia (CIN 2/3)</condition>
  <arm_group>
    <arm_group_label>PMED Delivery - groups 1 and 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive pNGVL4a-CRT/E7(detox) via gene gun at weeks 0, 4, 8 prior to therapeutic resection of their lesion at week 15.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>IM injections - groups 5 and 6</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive pNGVL4a-CRT/E7(detox) intramuscularly at weeks 0, 4, 8 prior to therapeutic resection of their lesion at week 15.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Intralesional delivery - group 3 and 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive pNGVL4a-CRT/E7(detox) intra-mucosally at weeks 0, 4, 8 prior to therapeutic resection of their lesion at week 15.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Intralesional delivery + imiquimod - group 7</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive pNGVL4a-CRT/E7(detox) intra-mucosally and imiquimod applied to the cervix at weeks 0, 4, 8 prior to therapeutic resection of their lesion at week 15.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>DNA vaccination</intervention_name>
    <description>vaccination with pNGVL4a-CRT/E7(detox)</description>
    <arm_group_label>IM injections - groups 5 and 6</arm_group_label>
    <arm_group_label>Intralesional delivery + imiquimod - group 7</arm_group_label>
    <arm_group_label>Intralesional delivery - group 3 and 4</arm_group_label>
    <arm_group_label>PMED Delivery - groups 1 and 2</arm_group_label>
    <other_name>Therapeutic vaccine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Gene gun vaccine</intervention_name>
    <description>8 micrograms (group 1) or 16 micrograms (group 2)</description>
    <arm_group_label>PMED Delivery - groups 1 and 2</arm_group_label>
    <other_name>PMED administration</other_name>
    <other_name>ND10 device</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>intramuscular vaccination</intervention_name>
    <description>1mg (group 3) or 3mg (group 4) of pNGVLra-CRT/E7(detox) administered intramuscularly</description>
    <arm_group_label>IM injections - groups 5 and 6</arm_group_label>
    <other_name>DNA vaccine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>intra-lesional vaccine administration</intervention_name>
    <description>1mg (group 5) or 3mg (group 6) of pNGVL4a-CRT/E7(detox)administered intra-lesionally</description>
    <arm_group_label>Intralesional delivery + imiquimod - group 7</arm_group_label>
    <arm_group_label>Intralesional delivery - group 3 and 4</arm_group_label>
    <other_name>Intra-lesional DNA vaccination</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>therapeutic resection of the lesion</intervention_name>
    <description>at week 15, all residual lesions will be resected</description>
    <arm_group_label>IM injections - groups 5 and 6</arm_group_label>
    <arm_group_label>Intralesional delivery + imiquimod - group 7</arm_group_label>
    <arm_group_label>Intralesional delivery - group 3 and 4</arm_group_label>
    <arm_group_label>PMED Delivery - groups 1 and 2</arm_group_label>
    <other_name>LEEP or cold knife conization</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>imiquimod</intervention_name>
    <description>imiquimod applied to the cervix by the physician</description>
    <arm_group_label>Intralesional delivery + imiquimod - group 7</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  patients with high grade cervical intraepithelial lesions (CIN2/3)

          -  patients whose lesions are HPV16+

          -  patients who are age 18 or older

          -  patients who are able to give informed consent

          -  patients who are immunocompetent

          -  patients who are not pregnant, committed to using adequate contraception if of
             childbearing age

          -  patients who have a minimum hemoglobin level of 9

        Exclusion Criteria:

          -  Patients with cytologic evidence of glandular dysplasia

          -  Patients with cytologic evidence of adenocarcinoma in situ

          -  Patients who are pregnant

          -  Patients with an active autoimmune disease

          -  Patients who are taking immunosuppressive medication

          -  Patients with concurrent malignancy except for nonmelanoma skin lesions

          -  Patients who have an allergy to gold.

          -  Patients with any evidence of damaged skin, or moles, scars, tattoos or marks at the
             proposed site(s) of administration that might interfere with the interpretation of
             local skin reactions.

          -  History or evidence of a physician-diagnosed chronic or recurrent inflammatory skin
             disease (e.g. psoriasis, eczema, atopic dermatitis, hypersensitivity) at the proposed
             site of administration in the past 5 years.

          -  Patients who have an active autoimmune disease or history of autoimmune disease
             requiring medical treatment with systemic immunosuppressants, including: inflammatory
             bowel disease, systemic vasculitis, scleroderma, psoriasis, multiple sclerosis,
             hemolytic anemic, or immune thrombocytopenia, rheumatoid arthritis, SLE, and Sjogren's
             syndrome, sarcoidosis. Asthma or COPD that does not require systemic corticosteroids
             or routine use of inhaled steroids is acceptable

          -  Patients who have received prior chrysotherapy (administration of gold salts to treat
             rheumatoid arthritis).

          -  Patients with a history of arterial or venous thrombosis

          -  Patients with non-healed wounds.

          -  Patients with a history of keloid formation ( ID delivery group only)

          -  Patients with a history of hepatitis B with persistent infection.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Cornelia L Trimble, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Johns Hopkins University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Alabama at Birmingham</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins Outpatient Center</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins Bayview Medical Center</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21224</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.hopkinsmedicine.org/cervicaldysplasia</url>
    <description>Johns Hopkins Center for Cervical Dysplasia</description>
  </link>
  <verification_date>July 2018</verification_date>
  <study_first_submitted>October 1, 2009</study_first_submitted>
  <study_first_submitted_qc>October 1, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 2, 2009</study_first_posted>
  <results_first_submitted>October 27, 2016</results_first_submitted>
  <results_first_submitted_qc>July 6, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">July 9, 2018</results_first_posted>
  <last_update_submitted>July 6, 2018</last_update_submitted>
  <last_update_submitted_qc>July 6, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">July 9, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>high grade cervical dysplasia</keyword>
  <keyword>treatment vaccine</keyword>
  <keyword>therapeutic</keyword>
  <keyword>HPV</keyword>
  <keyword>DNA vaccine</keyword>
  <keyword>gene therapy</keyword>
  <keyword>gene gun</keyword>
  <keyword>pre-cancerous</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma in Situ</mesh_term>
    <mesh_term>Cervical Intraepithelial Neoplasia</mesh_term>
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Imiquimod</mesh_term>
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>132 subjects signed consents to be screened for eligibility
93 subjects signed consents, but did not meet the eligibility criteria to start the study (screen failures)
39 subjects were assigned to a treatment group in the study</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>PMED Delivery - Groups 1 and 2</title>
          <description>Subjects will receive pNGVL4a-CRT/E7(detox) via gene gun at weeks 0, 4, 8 prior to therapeutic resection of their lesion at week 15.
DNA vaccination: vaccination with pNGVL4a-CRT/E7(detox)
Gene gun vaccine: 8 micrograms (group 1) or 16 micrograms (group 2)
therapeutic resection of the lesion: at week 15, all residual lesions will be resected</description>
        </group>
        <group group_id="P2">
          <title>IM Injections - Groups 5 and 6</title>
          <description>Subjects will receive pNGVL4a-CRT/E7(detox) intramuscularly at weeks 0, 4, 8 prior to therapeutic resection of their lesion at week 15.
DNA vaccination: vaccination with pNGVL4a-CRT/E7(detox)
intramuscular vaccination: 1mg (group 3) or 3mg (group 4) of pNGVLra-CRT/E7(detox) administered intramuscularly
therapeutic resection of the lesion: at week 15, all residual lesions will be resected</description>
        </group>
        <group group_id="P3">
          <title>Intralesional Delivery - Group 3 and 4</title>
          <description>Subjects will receive pNGVL4a-CRT/E7(detox) intra-mucosally at weeks 0, 4, 8 prior to therapeutic resection of their lesion at week 15.
DNA vaccination: vaccination with pNGVL4a-CRT/E7(detox)
intra-lesional vaccine administration: 1mg (group 5) or 3mg (group 6) of pNGVL4a-CRT/E7(detox)administered intra-lesionally
therapeutic resection of the lesion: at week 15, all residual lesions will be resected</description>
        </group>
        <group group_id="P4">
          <title>Intralesional Delivery + Imiquimod - Group 7</title>
          <description>Subjects will receive pNGVL4a-CRT/E7(detox) intra-mucosally and imiquimod applied to the cervix at weeks 0, 4, 8 prior to therapeutic resection of their lesion at week 15.
DNA vaccination: vaccination with pNGVL4a-CRT/E7(detox)
intra-lesional vaccine administration: 1mg (group 5) or 3mg (group 6) of pNGVL4a-CRT/E7(detox)administered intra-lesionally
therapeutic resection of the lesion: at week 15, all residual lesions will be resected
imiquimod: imiquimod applied to the cervix by the physician</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="11"/>
                <participants group_id="P3" count="11"/>
                <participants group_id="P4" count="7"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="9"/>
                <participants group_id="P3" count="9"/>
                <participants group_id="P4" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Pregnancy</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Participants enrolled in the study who received at least one study intervention</population>
      <group_list>
        <group group_id="B1">
          <title>PMED Delivery - Groups 1 and 2</title>
          <description>Subjects will receive pNGVL4a-CRT/E7(detox) via gene gun at weeks 0, 4, 8 prior to therapeutic resection of their lesion at week 15.
DNA vaccination: vaccination with pNGVL4a-CRT/E7(detox)
Gene gun vaccine: 8 micrograms (group 1) or 16 micrograms (group 2)
therapeutic resection of the lesion: at week 15, all residual lesions will be resected</description>
        </group>
        <group group_id="B2">
          <title>IM Injections - Groups 5 and 6</title>
          <description>Subjects will receive pNGVL4a-CRT/E7(detox) intramuscularly at weeks 0, 4, 8 prior to therapeutic resection of their lesion at week 15.
DNA vaccination: vaccination with pNGVL4a-CRT/E7(detox)
intramuscular vaccination: 1mg (group 3) or 3mg (group 4) of pNGVLra-CRT/E7(detox) administered intramuscularly
therapeutic resection of the lesion: at week 15, all residual lesions will be resected</description>
        </group>
        <group group_id="B3">
          <title>Intralesional Delivery - Group 3 and 4</title>
          <description>Subjects will receive pNGVL4a-CRT/E7(detox) intra-mucosally at weeks 0, 4, 8 prior to therapeutic resection of their lesion at week 15.
DNA vaccination: vaccination with pNGVL4a-CRT/E7(detox)
intra-lesional vaccine administration: 1mg (group 5) or 3mg (group 6) of pNGVL4a-CRT/E7(detox)administered intra-lesionally
therapeutic resection of the lesion: at week 15, all residual lesions will be resected</description>
        </group>
        <group group_id="B4">
          <title>Intralesional Delivery + Imiquimod - Group 7</title>
          <description>Subjects will receive pNGVL4a-CRT/E7(detox) intra-mucosally and imiquimod applied to the cervix at weeks 0, 4, 8 prior to therapeutic resection of their lesion at week 15.
DNA vaccination: vaccination with pNGVL4a-CRT/E7(detox)
intra-lesional vaccine administration: 1mg (group 5) or 3mg (group 6) of pNGVL4a-CRT/E7(detox)administered intra-lesionally
therapeutic resection of the lesion: at week 15, all residual lesions will be resected
imiquimod: imiquimod applied to the cervix by the physician</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="10"/>
            <count group_id="B2" value="11"/>
            <count group_id="B3" value="11"/>
            <count group_id="B4" value="7"/>
            <count group_id="B5" value="39"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25.5" lower_limit="20" upper_limit="44"/>
                    <measurement group_id="B2" value="26" lower_limit="21" upper_limit="35"/>
                    <measurement group_id="B3" value="26" lower_limit="23" upper_limit="35"/>
                    <measurement group_id="B4" value="26.14" lower_limit="24" upper_limit="29"/>
                    <measurement group_id="B5" value="25.91" lower_limit="20" upper_limit="44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="11"/>
                    <measurement group_id="B4" value="7"/>
                    <measurement group_id="B5" value="39"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="4"/>
                    <measurement group_id="B5" value="11"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="9"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="26"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Related Serious Adverse Events</title>
        <description>Presence of intervention-related serious adverse events as defined by CTCAE</description>
        <time_frame>9 months</time_frame>
        <population>Related Serious Adverse Events</population>
        <group_list>
          <group group_id="O1">
            <title>PMED Delivery - Groups 1 and 2</title>
            <description>Subjects will receive pNGVL4a-CRT/E7(detox) via gene gun at weeks 0, 4, 8 prior to therapeutic resection of their lesion at week 15.
DNA vaccination: vaccination with pNGVL4a-CRT/E7(detox)
Gene gun vaccine: 8 micrograms (group 1) or 16 micrograms (group 2)
therapeutic resection of the lesion: at week 15, all residual lesions will be resected</description>
          </group>
          <group group_id="O2">
            <title>IM Injections - Groups 5 and 6</title>
            <description>Subjects will receive pNGVL4a-CRT/E7(detox) intramuscularly at weeks 0, 4, 8 prior to therapeutic resection of their lesion at week 15.
DNA vaccination: vaccination with pNGVL4a-CRT/E7(detox)
intramuscular vaccination: 1mg (group 3) or 3mg (group 4) of pNGVLra-CRT/E7(detox) administered intramuscularly
therapeutic resection of the lesion: at week 15, all residual lesions will be resected</description>
          </group>
          <group group_id="O3">
            <title>Intralesional Delivery - Group 3 and 4</title>
            <description>Subjects will receive pNGVL4a-CRT/E7(detox) intra-mucosally at weeks 0, 4, 8 prior to therapeutic resection of their lesion at week 15.
DNA vaccination: vaccination with pNGVL4a-CRT/E7(detox)
intra-lesional vaccine administration: 1mg (group 5) or 3mg (group 6) of pNGVL4a-CRT/E7(detox)administered intra-lesionally
therapeutic resection of the lesion: at week 15, all residual lesions will be resected</description>
          </group>
          <group group_id="O4">
            <title>Intralesional Delivery + Imiquimod - Group 7</title>
            <description>Subjects will receive pNGVL4a-CRT/E7(detox) intra-mucosally and imiquimod applied to the cervix at weeks 0, 4, 8 prior to therapeutic resection of their lesion at week 15.
DNA vaccination: vaccination with pNGVL4a-CRT/E7(detox)
intra-lesional vaccine administration: 1mg (group 5) or 3mg (group 6) of pNGVL4a-CRT/E7(detox)administered intra-lesionally
therapeutic resection of the lesion: at week 15, all residual lesions will be resected
imiquimod: imiquimod applied to the cervix by the physician</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Related Serious Adverse Events</title>
          <description>Presence of intervention-related serious adverse events as defined by CTCAE</description>
          <population>Related Serious Adverse Events</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="11"/>
                <count group_id="O3" value="11"/>
                <count group_id="O4" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Absence of CIN2/3 Lesion by Week 15</title>
        <description>Number of participants with no CIN2/3 lesion at the week 15 visit</description>
        <time_frame>15 weeks</time_frame>
        <population>Number of participants who had no CIN2/3 at the week 15 resection</population>
        <group_list>
          <group group_id="O1">
            <title>PMED Delivery - Groups 1 and 2</title>
            <description>Subjects will receive pNGVL4a-CRT/E7(detox) via gene gun at weeks 0, 4, 8 prior to therapeutic resection of their lesion at week 15.
DNA vaccination: vaccination with pNGVL4a-CRT/E7(detox)
Gene gun vaccine: 8 micrograms (group 1) or 16 micrograms (group 2)
therapeutic resection of the lesion: at week 15, all residual lesions will be resected</description>
          </group>
          <group group_id="O2">
            <title>IM Injections - Groups 5 and 6</title>
            <description>Subjects will receive pNGVL4a-CRT/E7(detox) intramuscularly at weeks 0, 4, 8 prior to therapeutic resection of their lesion at week 15.
DNA vaccination: vaccination with pNGVL4a-CRT/E7(detox)
intramuscular vaccination: 1mg (group 3) or 3mg (group 4) of pNGVLra-CRT/E7(detox) administered intramuscularly
therapeutic resection of the lesion: at week 15, all residual lesions will be resected</description>
          </group>
          <group group_id="O3">
            <title>Intralesional Delivery - Group 3 and 4</title>
            <description>Subjects will receive pNGVL4a-CRT/E7(detox) intra-mucosally at weeks 0, 4, 8 prior to therapeutic resection of their lesion at week 15.
DNA vaccination: vaccination with pNGVL4a-CRT/E7(detox)
intra-lesional vaccine administration: 1mg (group 5) or 3mg (group 6) of pNGVL4a-CRT/E7(detox)administered intra-lesionally
therapeutic resection of the lesion: at week 15, all residual lesions will be resected</description>
          </group>
          <group group_id="O4">
            <title>Intralesional Delivery + Imiquimod - Group 7</title>
            <description>Subjects will receive pNGVL4a-CRT/E7(detox) intra-mucosally and imiquimod applied to the cervix at weeks 0, 4, 8 prior to therapeutic resection of their lesion at week 15.
DNA vaccination: vaccination with pNGVL4a-CRT/E7(detox)
intra-lesional vaccine administration: 1mg (group 5) or 3mg (group 6) of pNGVL4a-CRT/E7(detox)administered intra-lesionally
therapeutic resection of the lesion: at week 15, all residual lesions will be resected
imiquimod: imiquimod applied to the cervix by the physician</description>
          </group>
        </group_list>
        <measure>
          <title>Absence of CIN2/3 Lesion by Week 15</title>
          <description>Number of participants with no CIN2/3 lesion at the week 15 visit</description>
          <population>Number of participants who had no CIN2/3 at the week 15 resection</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="9"/>
                <count group_id="O4" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>41 weeks</time_frame>
      <group_list>
        <group group_id="E1">
          <title>PMED Delivery - Groups 1 and 2</title>
          <description>Subjects will receive pNGVL4a-CRT/E7(detox) via gene gun at weeks 0, 4, 8 prior to therapeutic resection of their lesion at week 15.
DNA vaccination: vaccination with pNGVL4a-CRT/E7(detox)
Gene gun vaccine: 8 micrograms (group 1) or 16 micrograms (group 2)
therapeutic resection of the lesion: at week 15, all residual lesions will be resected</description>
        </group>
        <group group_id="E2">
          <title>IM Injections - Groups 5 and 6</title>
          <description>Subjects will receive pNGVL4a-CRT/E7(detox) intramuscularly at weeks 0, 4, 8 prior to therapeutic resection of their lesion at week 15.
DNA vaccination: vaccination with pNGVL4a-CRT/E7(detox)
intramuscular vaccination: 1mg (group 3) or 3mg (group 4) of pNGVLra-CRT/E7(detox) administered intramuscularly
therapeutic resection of the lesion: at week 15, all residual lesions will be resected</description>
        </group>
        <group group_id="E3">
          <title>Intralesional Delivery - Group 3 and 4</title>
          <description>Subjects will receive pNGVL4a-CRT/E7(detox) intra-mucosally at weeks 0, 4, 8 prior to therapeutic resection of their lesion at week 15.
DNA vaccination: vaccination with pNGVL4a-CRT/E7(detox)
intra-lesional vaccine administration: 1mg (group 5) or 3mg (group 6) of pNGVL4a-CRT/E7(detox)administered intra-lesionally
therapeutic resection of the lesion: at week 15, all residual lesions will be resected</description>
        </group>
        <group group_id="E4">
          <title>Intralesional Delivery + Imiquimod - Group 7</title>
          <description>Subjects will receive pNGVL4a-CRT/E7(detox) intra-mucosally and imiquimod applied to the cervix at weeks 0, 4, 8 prior to therapeutic resection of their lesion at week 15.
DNA vaccination: vaccination with pNGVL4a-CRT/E7(detox)
intra-lesional vaccine administration: 1mg (group 5) or 3mg (group 6) of pNGVL4a-CRT/E7(detox)administered intra-lesionally
therapeutic resection of the lesion: at week 15, all residual lesions will be resected
imiquimod: imiquimod applied to the cervix by the physician</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="11"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Injection site reactions</sub_title>
                <description>Local injection site reactions</description>
                <counts group_id="E1" events="43" subjects_affected="8" subjects_at_risk="10"/>
                <counts group_id="E2" events="10" subjects_affected="6" subjects_at_risk="11"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>General pain, fever, malaise/fatigue</sub_title>
                <description>Abdominal discomfort, cramping, fatigue, flu like symptoms, headaches, muscle/joint aches, nausea, pain, pruritus</description>
                <counts group_id="E1" events="44" subjects_affected="8" subjects_at_risk="10"/>
                <counts group_id="E2" events="38" subjects_affected="8" subjects_at_risk="11"/>
                <counts group_id="E3" events="41" subjects_affected="8" subjects_at_risk="11"/>
                <counts group_id="E4" events="37" subjects_affected="7" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="11"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Limb numbness</sub_title>
                <counts group_id="E1" events="5" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Vaginal bleeding/spotting</sub_title>
                <description>vaginal bleeding or spotting</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="11"/>
                <counts group_id="E4" events="6" subjects_affected="1" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Laryngeal inflammation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Cornelia L. Trimble, MD</name_or_title>
      <organization>Johns Hopkins University</organization>
      <phone>410-502-0512</phone>
      <email>ctrimbl@jhmi.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

